Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma

NuklearMedizin

Volumn 46, Issue 6, 2007, Pages 239-243

  Krüger, Stefan ^a,b   Pauls, S ^a   Mottaghy, F M ^a   Buck, A K ^a   Schelzig, H ^a   Hombach, V ^a   Reske, S N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Computed tomography; Malignant pleural mesothelioma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPROMIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; SURVIVAL TIME;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; RADIOGRAPHY, THORACIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37349043894     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0091     Document Type: Article

References (16)

1. Ambrosini V, Rubello D, Nanni C et al. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur 2005; 8: 111-115.
2. Benard F, Sterman D, Smith RJ et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114: 713-722.
3. 18F-FDG PET for primary differential diagnosis of pleural processes. Nuklearmedizin 1999; 38: 319-322.
4. 18F] fluorodeoxyglucose. J Clin Oncol 2006; 24: 4587-4593.
5. Erasmus JJ, Truong MT, Smythe WR et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 2005; 129: 1364-1370.
6. Flores RM, Akhurst T, Gonen M et al. Positron emission tomography defines metastastic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003; 126: 11-16.
7. Flores RM, Akhurst T, Gonen M et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006; 132: 763-768.
8. 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003; 12: 1077-1082.
9. 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 2002; 9: 1144-1149.
10. Lardinois D, Weder W, Hany TF et al. Staging of non-small-lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
11. 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 2004; 2: 149-154.
12. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 15: 1591-1603.
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-1128.
14. 18F-fluorodeoxy-glucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000; 1: 128-133.
15. Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 2006; 21: 146-153.
16. 18F-fluorodeoxyglucose and PET. Comparison with computed tomography. Clin Positron Imaging 2000; 4: 165.